NEW YORK, August 13, 2025 — Leads & Copy — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a clinical biotechnology company, has released its financial results for the second quarter of 2025, highlighting positive topline results from the Phase 2 TRANQUILITY trial of pacibekitug.
The trial demonstrated rapid, deep, and durable reductions in high-sensitivity C-reactive protein with quarterly dosing. Additional data from the trial will be presented at the European Society of Cardiology Congress in August 2025.
Tourmaline is on track to initiate a Phase 2 proof-of-concept trial in abdominal aortic aneurysm in the second half of 2025 and is planning a Phase 3 cardiovascular outcomes trial in atherosclerotic cardiovascular disease. The company’s cash, cash equivalents, and investments of $256.4 million as of June 30, 2025, are expected to provide cash runway into the second half of 2027.
According to Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline, the second quarter was transformative with the first data readout for pacibekitug.
The company is developing transformative medicines to improve the lives of patients with immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential.
Media Contact:
Sarah Mishek
SMishek@ScientPR.com
Investor Contact:
Lee M. Stern
lstern@meruadvisors.com
Source: Tourmaline Bio
